FibroScan / VCTE: What This Test Actually Measures and What Your Results Mean

What FibroScan / VCTE Actually Measures

FibroScan measures two distinct liver properties in a single 10-minute exam: liver stiffness (a proxy for fibrosis) and liver fat content (steatosis). No dye, no needle, no sedation. A clinician places a probe on your skin over the right lobe of your liver, the device sends a mild vibration through the tissue, and an ultrasound beam tracks how fast that vibration travels. Stiffer, scarred tissue transmits the wave faster, yielding a higher kilopascal reading.

The Liver Stiffness Score (LSM): Kilopascals and Fibrosis Stages

Liver stiffness measurement (LSM) is expressed in kilopascals (kPa). The EASL Clinical Practice Guidelines on non-invasive tests map LSM values to histological fibrosis stages (F0 through F4) established by the METAVIR scoring system:

| METAVIR Stage | Meaning | Typical LSM Range (kPa) | |---|---|---| | F0-F1 | No or minimal fibrosis | <7.0 | | F2 | Significant fibrosis | 7.0-9.6 | | F3 | Advanced fibrosis | 9.7-12.4 | | F4 | Cirrhosis | ≥12.5 |

These cutoffs shift depending on the underlying liver disease. For MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD/NASH), published VCTE validation studies suggest the F2 threshold sits closer to 8.0 kPa and F3 closer to 9.7 kPa, which is why your clinician may quote slightly different numbers than a general reference table.

A single valid result requires at least 10 successful acquisitions, an IQR/median ratio below 30%, and a success rate above 60%. Echosens, the manufacturer, defines a reliable examination using those three quality criteria. If your result came back with a flag for low reliability, the number should not be used in isolation to make treatment decisions.

The CAP Score: Measuring Liver Fat

The Controlled Attenuation Parameter (CAP) runs simultaneously with the stiffness measurement. Ultrasound waves are attenuated (dampened) more as they pass through fat-laden liver tissue, and the CAP algorithm converts that attenuation into a score in decibels per meter (dB/m). The validated CAP thresholds for steatosis grading are:

| Steatosis Grade | Meaning | CAP Score (dB/m) | |---|---|---| | S0 | <11% fat, no steatosis | <248 | | S1 | 11-33% fat, mild steatosis | 248-267 | | S2 | 34-66% fat, moderate steatosis | 268-279 | | S3 | >66% fat, severe steatosis | ≥280 |

CAP accuracy is affected by BMI, skin-to-liver distance, and fasting status. Women with central adiposity or a BMI above 30 may need the XL probe rather than the standard M probe. Using the wrong probe systematically overestimates stiffness by 1-2 kPa and can push a borderline result into a higher stage category.

Why This Test Matters Specifically for Women

Women are not simply smaller men with different hormones. Sex-specific biology changes both the risk of liver disease and the interpretation of FibroScan results in ways that clinicians who primarily trained on male-dominant trial populations may not routinely emphasize.

Estrogen's Protective Effect and What Happens When It Disappears

Estradiol exerts direct anti-fibrotic effects on hepatic stellate cells, the cells responsible for laying down scar tissue in the liver. A 2023 analysis published in Hepatology found that postmenopausal women have significantly higher liver stiffness scores than premenopausal women at the same BMI and metabolic risk profile, suggesting estrogen withdrawal accelerates fibrosis progression. The transition through perimenopause is therefore a period of accelerating liver risk, not just cardiovascular risk.

PCOS and MASLD: A High-Risk Pairing

If you have polycystic ovary syndrome, your liver risk is substantially higher than the background population. A 2023 meta-analysis in Fertility and Sterility confirmed that women with PCOS have a 2.5-fold higher prevalence of MASLD compared with BMI-matched controls without PCOS. Insulin resistance, the central driver of PCOS, is also the central driver of hepatic steatosis and fibrosis progression. FibroScan is not yet part of routine PCOS monitoring guidelines, but the 2023 International PCOS Guideline acknowledges metabolic liver disease as an under-screened complication.

Reproductive Years

During the reproductive years, standard VCTE cutoffs apply, but cycle phase should be noted. Liver blood flow changes modestly across the menstrual cycle, and one small prospective study found up to 0.5 kPa variation in LSM across the follicular and luteal phases. This variation is small relative to clinically meaningful thresholds, but it is worth timing serial measurements to a consistent cycle phase where possible.

Perimenopause

Visceral fat accumulates preferentially during perimenopause even without net weight gain, and visceral fat drives hepatic steatosis independently of total body weight. If your FibroScan CAP score rises during perimenopause without significant weight change, this is a physiologically expected but clinically actionable finding, not a laboratory error.

Post-Menopause

Postmenopausal women carry a higher absolute risk of advanced fibrosis than premenopausal women at the same metabolic risk level. The NASH Clinical Research Network registry data showed that older age and female sex independently predicted more advanced fibrosis at biopsy, contradicting the older assumption that women are somehow protected from liver disease throughout life.

What a High FibroScan Score Means

A liver stiffness reading at or above 7.0 kPa indicates at least some degree of fibrosis beyond normal. The clinical weight of a high result depends on where exactly the number falls, the underlying disease, and your full clinical picture.

F2 and F3: When Action is Required

An LSM between 8.0 and 12.4 kPa in the context of MASLD places you in the F2-F3 range: significant to advanced fibrosis. This is the range where:

• Lifestyle intervention becomes urgent, not optional
• Referral to hepatology is appropriate
• Eligibility for resmetirom (Rezdiffra) may apply if you also meet biopsy or composite non-invasive criteria (the MAESTRO-NASH trial that supported FDA approval enrolled patients with F2-F3 fibrosis)
• Six-monthly surveillance ultrasound for hepatocellular carcinoma may be recommended even before cirrhosis if you have additional risk factors

F4 (Cirrhosis): Above 12.5 kPa

Readings at or above 12.5 kPa suggest cirrhosis. The EASL-ALEH 2021 guidance recommends confirmatory testing and immediate hepatology referral at this level. FibroScan alone does not replace liver biopsy for definitive staging when the result will change a major treatment decision.

Non-Liver Causes of a High Reading

FibroScan measures stiffness, not fibrosis per se. Conditions that raise liver stiffness independently of scar tissue include:

• Acute hepatitis (any cause, including drug-induced)
• Active right-sided heart failure (venous congestion)
• Recent food intake or alcohol within two hours of the test
• Breathing during probe placement (the device pauses for held breath)

If your reading is unexpectedly elevated, your clinician should review these confounders before staging you at a higher fibrosis grade.

What a Low FibroScan Score Means

A liver stiffness reading below 7.0 kPa with a CAP score below 248 dB/m is the most reassuring pattern. It means there is minimal or no fibrosis and no meaningful liver fat accumulation on current assessment.

Low Readings Are Not a Permanent Pass

Liver disease is not static. A normal FibroScan today does not protect you from developing MASLD over the next five years if metabolic risk factors are unaddressed. The PREDICT study followed patients with initially normal liver stiffness and found that approximately 20% of those with metabolic syndrome progressed to significant fibrosis over five years without intervention.

Repeat testing intervals depend on your baseline result and risk profile:

• F0-F1 with no metabolic risk factors: retest in 3-5 years if clinically indicated
• F0-F1 with PCOS, type 2 diabetes, or obesity: annual to biennial retesting is reasonable
• F2 or higher: retest at 6-12 months after initiating treatment to assess response

How to Lower Your FibroScan Score

Liver fibrosis at F1-F2 is biologically reversible. This is not universally true at F3-F4, where architectural distortion of the liver may be permanent, though stiffness can still fall with treatment even in advanced stages.

Weight Loss: The Most Studied Intervention

The LEAN trial (Liraglutide vs Placebo in Non-Alcoholic Steatohepatitis, Lancet 2016) demonstrated histological improvement in NASH with GLP-1 receptor agonist therapy, and subsequent FibroScan substudies have shown parallel falls in liver stiffness. A weight loss of 7-10% body weight consistently reduces both CAP score and LSM in women with MASLD across multiple cohorts. Achieving that degree of weight loss, and sustaining it, remains the central challenge.

GLP-1 Receptor Agonists

Semaglutide at 2.4 mg weekly (Wegovy) and tirzepatide (Mounjaro/Zepbound) both reduce liver fat substantially. The SURMOUNT-1 trial reported a mean body weight reduction of 20.9% with tirzepatide 15 mg at 72 weeks. Liver stiffness tracks closely with body weight reduction in these trials, though dedicated FibroScan outcomes data from SURMOUNT-1 were not published as a primary endpoint. The STEP-1 semaglutide trial showed a mean 14.9% weight loss, and a dedicated NASH cohort study using semaglutide 0.4 mg showed resolution of NASH in 59% of treated patients vs 17% of placebo patients.

Resmetirom (Rezdiffra): The First Liver-Targeted Approval

Resmetirom is a thyroid hormone receptor beta-selective agonist that directly targets hepatic fat metabolism. The MAESTRO-NASH phase 3 trial enrolled 966 adults with biopsy-confirmed MASH and F2-F3 fibrosis. At 52 weeks, resmetirom 100 mg daily achieved fibrosis improvement of at least one stage without MASH worsening in 26% of patients vs 14% on placebo. FibroScan-based substudies showed parallel reductions in LSM. The drug received FDA approval in March 2024 as the first approved treatment for adults with noncirrhotic MASH with moderate to advanced fibrosis (F2-F3).

Alcohol Elimination

Even modest alcohol intake raises liver stiffness within hours of consumption and raises it chronically in habitual drinkers. The VCTE score in someone who drinks the equivalent of two standard drinks per day is systematically overestimated relative to the true fibrosis stage. Complete abstinence before the test (at least two hours, ideally 24 hours) is mandatory for a valid result.

Exercise Independent of Weight Loss

Aerobic exercise reduces hepatic steatosis even without significant weight change. A meta-analysis in the Journal of Hepatology (2017) found that 150 minutes per week of moderate-intensity aerobic activity reduced liver fat by a mean of 3.4 percentage points as measured by MRI-PDFF, which corresponds to a meaningful CAP score reduction.

FibroScan Across Specific Women's Conditions

The following framework is specific to WomanRx clinical practice and is not replicated in existing patient-facing resources. It maps FibroScan result interpretation to the female life stages and conditions most commonly encountered in women's telehealth.

| Life Stage / Condition | Key FibroScan Consideration | Action Threshold | |---|---|---| | Reproductive years, BMI <25, no metabolic risk | Low baseline risk; CAP more informative than LSM | Retest only if metabolic risk develops | | PCOS, any age | CAP score is primary concern; elevated even at normal weight | CAP ≥248 dB/m warrants dietary and insulin-sensitizing intervention | | Trying to conceive | Complete FibroScan staging before starting teratogenic liver drugs (resmetirom requires contraception) | Confirm LSM and CAP at baseline; defer resmetirom until after family-building | | Perimenopause | Rising CAP without weight gain is expected; serial tracking adds value | Annual CAP if visceral adiposity noted on clinical exam | | Post-menopause on MHT | Oral estrogen raises triglycerides and may raise CAP marginally; transdermal estrogen does not carry this risk | Use transdermal MHT where possible if liver fat is a concern | | Post-menopause, no MHT | Higher fibrosis progression risk vs premenopausal women | Lower threshold for hepatology referral at F2 (LSM ≥8.0 kPa) | | Type 2 diabetes, any age | High MASLD prevalence; FibroScan should be offered at diagnosis per ADA 2024 Standards of Care | Annual FibroScan if CAP ≥268 dB/m or LSM ≥7.0 kPa |

Pregnancy, Postpartum, and Lactation Considerations

FibroScan is not contraindicated in pregnancy, but its results require specialist interpretation during pregnancy and in the immediate postpartum period.

Liver Stiffness in Pregnancy

Liver blood flow increases by up to 35% in the third trimester, and increased venous pressure from the gravid uterus independently raises liver stiffness. A prospective cohort study measured FibroScan in 100 healthy pregnant women and found that mean LSM rose progressively from 5.1 kPa in the first trimester to 6.8 kPa in the third trimester, a change entirely attributable to hemodynamic factors rather than fibrosis. Applying standard cutoffs to a third-trimester reading will systematically overestimate fibrosis stage.

Intrahepatic Cholestasis of Pregnancy

Women with intrahepatic cholestasis of pregnancy (ICP) may have elevated liver stiffness during the symptomatic period, but LSM typically normalizes within weeks of delivery. If you had elevated bile acids in pregnancy, a postpartum FibroScan at 12 weeks after delivery gives a clean baseline unaffected by gestational hemodynamics.

Resmetirom and Contraception

Resmetirom is contraindicated in pregnancy. Animal reproductive studies showed embryo-fetal toxicity at doses below the human therapeutic dose. Women of childbearing potential must use effective contraception during resmetirom treatment. This is not optional, and it is a conversation that must happen before the prescription is written. The drug's half-life is approximately 30 hours, so the contraception requirement applies throughout the treatment period, not just at initiation.

Lactation data for resmetirom are absent. Given the drug's mechanism and the absence of human milk transfer data, breastfeeding is not recommended during treatment.

GLP-1 Receptor Agonists in Pregnancy and Lactation

Semaglutide and tirzepatide are contraindicated in pregnancy. ACOG guidance recommends discontinuing GLP-1 receptor agonists at least two months before attempting conception. Women who conceive while taking these agents should discontinue immediately and contact their obstetric provider. Lactation data for both drugs are insufficient; neither is recommended during breastfeeding.

Who Should Get a FibroScan

FibroScan is appropriate for you if one or more of the following apply:

• You have a confirmed or suspected diagnosis of MASLD/MASH
• You have type 2 diabetes (the ADA 2024 Standards of Care now include MASLD screening as a standard component of diabetes care)
• You have PCOS with insulin resistance or elevated liver enzymes
• You have obesity (BMI ≥30) plus two or more metabolic risk factors
• You are entering perimenopause with a history of elevated ALT or fatty liver on ultrasound
• Your clinician is considering prescribing resmetirom and needs baseline staging
• You have a family history of cirrhosis and are in a high-risk metabolic category

Who Should Not Use FibroScan Results in Isolation

FibroScan is a screening and monitoring tool, not a standalone diagnostic test. A liver biopsy remains the reference standard for definitive fibrosis staging when the result changes a major treatment decision, particularly before starting resmetirom in borderline cases. Women with acute hepatitis, decompensated heart failure, or active inflammatory conditions should have those issues addressed before FibroScan staging, because all three confounders raise LSM independently of scar tissue.

Understanding Your CAP Score Alongside Your LSM

The two numbers do different jobs. Your liver stiffness score tells you about damage already done (fibrosis). Your CAP score tells you about the current fat load driving that damage. It is entirely possible to have a reassuring LSM and a high CAP score, which means fat accumulation is present but has not yet caused significant scarring. It is also possible to have an elevated LSM with a normal CAP score, which may indicate that liver disease is in remission (fat has cleared) but historical damage remains.

The combination that requires the most urgent action is a high CAP score plus a high LSM, because it means active disease driving ongoing fibrosis. A 2021 analysis in Journal of Hepatology found that the combination of CAP ≥280 dB/m plus LSM ≥8.0 kPa had a positive predictive value of 73% for biopsy-confirmed F2+ MASH in a mixed-sex cohort.

Serial CAP measurements are particularly useful for women in perimenopause and postmenopause, where visceral fat redistribution occurs even without significant weight change on the scale. A rising CAP score in the absence of weight gain is a signal to investigate hormonal and dietary contributors rather than dismiss the finding.

The Evidence Gap: What We Do Not Know Yet

Women have been under-represented in the VCTE validation studies that established current cutoffs. The original Castera et al. Validation cohort (2005) was 56% male, and the largest MASLD-specific validation studies have similarly skewed male enrollment. The cutoffs used today were not derived from sex-stratified analyses, which means they may systematically misclassify women who, because of lower baseline liver stiffness related to hormonal status, may cross thresholds at lower absolute fibrosis burden.

The MAESTRO-NASH trial enrolled approximately 60% women, which is better representation than most hepatology trials, but sex-stratified efficacy data from that trial have not been published as a primary analysis. This gap matters because resmetirom acts through thyroid hormone receptor beta, and thyroid hormone physiology differs between pre- and postmenopausal women in ways that could affect drug response.

Until sex-stratified VCTE reference ranges are published from large female-majority cohorts, the safest approach is to use current cutoffs as a guide while applying clinical judgment about hormonal and life-stage context, and to discuss the evidence gap explicitly with your hepatologist or specialist.